Clinical trial results:
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of KBP-5074, a Mineralocorticoid Receptor Antagonist, in Subjects with Uncontrolled Hypertension Who Have Moderate or Severe (Stage 3b/4) Chronic Kidney Disease

Summary

EudraCT number	2021-003636-88
Trial protocol	ES HU BG CZ LT PL HR
Global end of trial date	10 July 2024

Results information

Result version number	v1 (current)
This version publication date	26 December 2025
First version publication date	26 December 2025

Trial information

Trial identification

Sponsor protocol code	KBP5074-3-001

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT04968184
WHO universal trial number (UTN)	-
Other trial identifiers	IND: 117743

Notes:

Sponsors

Sponsor organisation name	Novo Nordisk A/S
Sponsor organisation address	Novo Alle, Bagsvrd, Denmark, 2880
Public contact	Clinical Reporting Office (2834), Novo Nordisk A/S, clinicaltrials@novonordisk.com
Scientific contact	Clinical Reporting Office (2834), Novo Nordisk A/S, clinicaltrials@novonordisk.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	11 September 2024
Is this the analysis of the primary completion data?	No

Global end of trial reached?	Yes
Global end of trial date	10 July 2024
Was the trial ended prematurely?	Yes

Notes:

General information about the trial

Main objective of the trial:

The primary objective of this study is to evaluate the efficacy and durability of KBP-5074 in reducing systolic blood pressure (SBP).

Protection of trial subjects:

As Novo Nordisk A/S was not the Sponsor of the study at the time it was conducted, Novo Nordisk A/S is unable to confirm that this study was conducted in accordance with the protocol and consensus ethical principles derived from international guidelines including the Declaration of Helsinki (Version 2013), International Council for Harmonisation (ICH) guidelines for Good Clinical Practices (GCP), the European Union Clinical Trials Directive 2001/20/EC (EUCTD), IRB/IECs, and all other applicable laws and regulations.
Novo Nordisk A/S is also unable to confirm the accuracy of factual assertions contained herein concerning the conduct of the study.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	05 November 2021
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Poland: 3
Country: Number of subjects enrolled	Spain: 7
Country: Number of subjects enrolled	Croatia: 1
Country: Number of subjects enrolled	Bulgaria: 4
Country: Number of subjects enrolled	Czechia: 11
Country: Number of subjects enrolled	Germany: 13
Country: Number of subjects enrolled	Hungary: 9
Country: Number of subjects enrolled	Latvia: 2
Country: Number of subjects enrolled	Lithuania: 2
Country: Number of subjects enrolled	Australia: 9
Country: Number of subjects enrolled	Bosnia and Herzegovina: 52
Country: Number of subjects enrolled	Canada: 1
Country: Number of subjects enrolled	China: 78
Country: Number of subjects enrolled	Georgia: 127
Country: Number of subjects enrolled	Korea, Republic of: 7
Country: Number of subjects enrolled	Malaysia: 21

Country: Number of subjects enrolled	Serbia: 22
Country: Number of subjects enrolled	United States: 184
Country: Number of subjects enrolled	South Africa: 3
Worldwide total number of subjects	556
EEA total number of subjects	52

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	180
From 65 to 84 years	363
85 years and over	13

Subject disposition

Recruitment

Recruitment details:

This study was conducted at 132 sites that randomised subjects in 21 countries globally, from 27 December 2021 (first subject enrolled) to 10 July 2024 (last subject completed).

Pre-assignment

Screening details:

Subjects who met the inclusion criteria and none of the exclusion criteria were enrolled to the study. All study assessments were performed as per the schedule of assessment. Of the 1246 subjects screened, 690 were screen failures and 554 subjects were randomized to treatment while 2 subjects were not treated.

Period 1

Period 1 title	24-week Double-Blind Treatment Period
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator, Monitor, Carer

Arms

Are arms mutually exclusive?	Yes
Arm title	KBP-5074

Arm description:

Subjects received 0.25 mg to a maximum dose of 0.5 mg of KBP-5074 once daily (QD).

Arm type	Experimental
Investigational medicinal product name	KBP-5074
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Film-coated tablet
Routes of administration	Oral use

Dosage and administration details:

KBP-5074 tablets were administered orally.

Arm title	Placebo

Arm description:

Subjects received placebo matching to KBP-5074 QD.

Arm type	Placebo
Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Film-coated tablet
Routes of administration	Oral use

Dosage and administration details:

Placebo tablets were administered orally.

Number of subjects in period 1	KBP-5074	Placebo
Started	281	275
Completed	251	246
Not completed	30	29
Consent withdrawn by subject	20	20
Adverse event, non-fatal	2	-
Death	2	-
Noncompliance With the Protocol	-	1
Study Terminated by Sponsor	1	2
Lost to follow-up	5	3
Noncompliance With Study Drug	-	1
Randomized in Error	-	2

Period 2

Period 2 title	24-week Open-Label (OL) Treatment Period
Is this the baseline period?	No
Allocation method	Non-randomised - controlled
Blinding used	Not blinded

Arms

Are arms mutually exclusive?	Yes
Arm title	KBP-5074 - OL

Arm description:

Subjects received 0.25 mg to a maximum dose of 0.5 mg of KBP-5074 QD.

Arm type	Experimental
Investigational medicinal product name	KBP-5074
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Film-coated tablet
Routes of administration	Oral use

Dosage and administration details:

KBP-5074 tablets were administered orally.

Arm title	Placebo - OL

Arm description:

Subjects received placebo matching to KBP-5074 QD.

Arm type	Placebo
Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Film-coated tablet
Routes of administration	Oral use

Dosage and administration details:

Placebo tablets were administered orally.

Number of subjects in period 2	KBP-5074 - OL	Placebo - OL
Started	251	246
Completed	125	118
Not completed	126	128
Consent withdrawn by subject	6	9
Trial Site Terminated by Sponsor	10	5
Adverse event, non-fatal	2	1
Death	3	1
Noncompliance With the Protocol	-	1
Study Terminated by Sponsor	100	110
Lost to follow-up	5	1

Period 3	
Period 3 title	4-week Double-Blind Withdrawal(W) Period
Is this the baseline period?	No
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator, Monitor, Carer

Arms	
Are arms mutually exclusive?	Yes
Arm title	KBP-5074 - W
Arm description: Subjects received 0.25 mg to a maximum dose of 0.5 mg of KBP-5074 QD.	
Arm type	Experimental
Investigational medicinal product name	KBP-5074
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Film-coated tablet
Routes of administration	Oral use
Dosage and administration details: KBP-5074 tablets were administered orally.	
Arm title	Placebo - W
Arm description: Subjects received placebo matching to KBP-5074 QD.	
Arm type	Placebo

Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Film-coated tablet
Routes of administration	Oral use

Dosage and administration details:

Placebo tablets were administered orally.

Number of subjects in period 3	KBP-5074 - W	Placebo - W
Started	125	118
Completed	115	108
Not completed	10	10
Consent withdrawn by subject	2	1
Trial Site Terminated by Sponsor	2	-
Study Terminated by Sponsor	6	8
Lost to follow-up	-	1

Baseline characteristics

Reporting groups	
Reporting group title	KBP-5074
Reporting group description:	
Subjects received 0.25 mg to a maximum dose of 0.5 mg of KBP-5074 once daily (QD).	
Reporting group title	Placebo
Reporting group description:	
Subjects received placebo matching to KBP-5074 QD.	

Reporting group values	KBP-5074	Placebo	Total
Number of subjects	281	275	556
Age categorical			
Units: Subjects			
In utero			0
Preterm newborn infants (gestational age < 37 wks)			0
Newborns (0-27 days)			0
Infants and toddlers (28 days-23 months)			0
Children (2-11 years)			0
Adolescents (12-17 years)			0
Adults (18-64 years)			0
From 65-84 years			0
85 years and over			0
Age continuous			
The intent to treat (ITT) population was defined as all randomised subjects after removal of subjects from site 508.			
Units: years			
arithmetic mean	67.4	67.9	
standard deviation	± 10.87	± 10.85	-
Gender categorical			
The ITT population was defined as all randomised subjects after removal of subjects from site 508.			
Units: Subjects			
Female	98	116	214
Male	183	159	342

End points

End points reporting groups

Reporting group title	KBP-5074
Reporting group description:	
Subjects received 0.25 mg to a maximum dose of 0.5 mg of KBP-5074 once daily (QD).	
Reporting group title	Placebo
Reporting group description:	
Subjects received placebo matching to KBP-5074 QD.	
Reporting group title	KBP-5074 - OL
Reporting group description:	
Subjects received 0.25 mg to a maximum dose of 0.5 mg of KBP-5074 QD.	
Reporting group title	Placebo - OL
Reporting group description:	
Subjects received placebo matching to KBP-5074 QD.	
Reporting group title	KBP-5074 - W
Reporting group description:	
Subjects received 0.25 mg to a maximum dose of 0.5 mg of KBP-5074 QD.	
Reporting group title	Placebo - W
Reporting group description:	
Subjects received placebo matching to KBP-5074 QD.	

Primary: Change in seated trough cuff Systolic Blood Pressure (SBP) from baseline to Week 12

End point title	Change in seated trough cuff Systolic Blood Pressure (SBP) from baseline to Week 12
End point description:	
Efficacy of KBP-5074 in reducing SBP by assessing change in seated trough cuff SBP for KBP-5074 dose regimen compared to placebo, was evaluated. The intent-to-treat (ITT) Population was defined as all randomised subjects after removal of subjects from site 508.	
End point type	Primary
End point timeframe:	
From baseline to Week 12	

End point values	KBP-5074	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	267	255		
Units: mm Hg (millimeters of mercury)				
arithmetic mean (standard deviation)	-12.9 (± 18.02)	-12.4 (± 18.73)		

Statistical analyses

Statistical analysis title	Statistical comparison of KBP-5074 v/s Placebo

Statistical analysis description:

Difference (KBP-5074 QD - Placebo QD) between adjusted least square (LS) means of change from baseline

Comparison groups	KBP-5074 v Placebo
Number of subjects included in analysis	522
Analysis specification	Pre-specified
Analysis type	other[1]
P-value	= 0.572
Method	ANCOVA
Parameter estimate	Difference between adjusted LS means
Point estimate	-0.8
Confidence interval	
level	95 %
sides	2-sided
lower limit	-3.7
upper limit	2

Notes:

[1] - Adjusted Least Square (LS) Means are estimated using an analysis of covariance (ANCOVA) model with change in seated trough cuff SBP from baseline to Week 12 as the outcome variable.

Primary: Change in seated trough cuff SBP from Week 48 to Week 52

End point title	Change in seated trough cuff SBP from Week 48 to Week 52

End point description:

Durability of KBP-5074 in reducing SBP by assessing change in seated trough cuff SBP for the KBP-5074 dose regimen compared to placebo, was evaluated.

The Randomised Withdrawal Population was defined as all randomised subjects, after removal of subjects from site 508, who were randomised at the Week 48 Visit into the Randomised Double-Blind Withdrawal Period and had at least 1 SBP measurement after the Week 48 Visit.

Imputation of missing Week 52 SBP was done using MI assuming Missing at Random (MAR).
The analysis of mean change in seated trough cuff SBP from Week 48 to Week 52 using retrieved dropout-based MI (Randomised Withdrawal Population) was not performed because the observed data for dropouts was too limited. The sensitivity analysis using MI assuming MAR was used instead.

End point type	Primary

End point timeframe:

Change from Week 48 to Week 52

End point values	KBP-5074 - W	Placebo - W		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	98	102		
Units: mm Hg				
arithmetic mean (standard deviation)	-0.9 (± 15.45)	0.9 (± 15.91)		

Statistical analyses

Statistical analysis title	Statistical comparison of KBP-5074 v/s Placebo

Statistical analysis description:

Difference (KBP-5074 QD - Placebo QD) between adjusted LS means of change from baseline

Comparison groups	Placebo - W v KBP-5074 - W
Number of subjects included in analysis	200
Analysis specification	Pre-specified
Analysis type	other[2]
P-value	= 0.789
Method	ANCOVA
Parameter estimate	Adjusted LS mean
Point estimate	-0.5
Confidence interval	
level	95 %
sides	2-sided
lower limit	-4.4
upper limit	3.3

Notes:

[2] - Adjusted LS Means are estimated using an ANCOVA model with change in seated trough cuff SBP from Week 48 to Week 52 as the outcome variable.

Secondary: Change in seated trough cuff SBP from baseline to Week 24

End point title	Change in seated trough cuff SBP from baseline to Week 24

End point description:

Efficacy and durability of KBP-5074 in reducing SBP by assessing change in seated trough cuff SBP, were evaluated.

The ITT Population was defined as all randomised subjects after removal of subjects from site 508.

End point type	Secondary

End point timeframe:

From baseline to Week 24

End point values	KBP-5074	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	242	232		
Units: mm Hg				
arithmetic mean (standard deviation)	-15.3 (± 17.76)	-12.8 (± 17.30)		

Statistical analyses

Statistical analysis title	Statistical comparison of KBP-5074 v/s Placebo

Statistical analysis description:

Difference (KBP-5074 QD - Placebo QD) between adjusted LS means of change from baseline

Comparison groups	KBP-5074 v Placebo

Number of subjects included in analysis	474
Analysis specification	Pre-specified
Analysis type	other[3]
P-value	= 0.096
Method	ANCOVA
Parameter estimate	Difference Between Adjusted LS Means
Point estimate	-2.4
Confidence interval	
level	95 %
sides	2-sided
lower limit	-5.2
upper limit	0.4

Notes:

[3] - Adjusted LS Means were estimated using an ANCOVA model with change in seated trough cuff SBP from baseline to Week 24 as the outcome variable.

Secondary: Changes in seated trough cuff diastolic blood pressure (DBP) from baseline to Week 12

End point title	Changes in seated trough cuff diastolic blood pressure (DBP) from baseline to Week 12

End point description:

Effect of KBP-5074 on DBP by assessing change in seated trough cuff DBP, was evaluated.

The ITT Population was defined as all randomised subjects after removal of subjects from site 508.

End point type	Secondary

End point timeframe:

From baseline to Week 12

End point values	KBP-5074	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	267	255		
Units: mm Hg				
arithmetic mean (standard deviation)	-6.3 (± 11.74)	-5.6 (± 11.53)		

Statistical analyses

Statistical analysis title	Statistical comparison of KBP-5074 v/s Placebo

Statistical analysis description:

Difference (KBP-5074 QD - Placebo QD) between adjusted LS means of change from baseline

Comparison groups	KBP-5074 v Placebo
Number of subjects included in analysis	522
Analysis specification	Pre-specified
Analysis type	other[4]
P-value	= 0.515
Method	ANCOVA
Parameter estimate	Difference between adjusted LS means
Point estimate	-0.7

Confidence interval	
level	95 %
sides	2-sided
lower limit	-2.7
upper limit	1.4

Notes:

[4] - Adjusted LS Means were estimated using an ANCOVA model with change in seated trough cuff DBP from baseline to Week 12 as the outcome variable.

Secondary: Changes in seated trough cuff SBP from baseline to Week 48

End point title	Changes in seated trough cuff SBP from baseline to Week 48

End point description:

Effect of KBP-5074 on SBP by assessing change in seated trough cuff SBP, was evaluated.

The ITT Population was defined as all randomised subjects after removal of subjects from site 508.

Subjects in Placebo QD group were switched to KBP-5074 QD after Week 24.

End point type	Secondary

End point timeframe:

From baseline to Week 48

End point values	KBP-5074 - OL	Placebo - OL		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	140	143		
Units: mm Hg				
arithmetic mean (standard deviation)	-13.1 (± 16.64)	-17.2 (± 18.23)		

Statistical analyses

Statistical analysis title	Statistical comparison of KBP-5074 v/s Placebo

Statistical analysis description:

Difference (KBP-5074 QD -> KBP-5074 QD – Placebo QD -> KBP-5074 QD) between LS means of change from baseline

Comparison groups	KBP-5074 - OL v Placebo - OL
Number of subjects included in analysis	283
Analysis specification	Pre-specified
Analysis type	other[5]
P-value	= 0.095
Method	Mixed models analysis
Parameter estimate	Difference between LS means
Point estimate	2.9
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.5
upper limit	6.4

Notes:

[5] - Estimated using a mixed-effect repeated model with change in seated trough cuff SBP from baseline to Week 48 as the outcome variable. The model uses an Unstructured covariance matrix.

Secondary: Changes in urinary albumin: creatinine ratio (UACR) from baseline to Week 12 for subjects with UACR ≥30 mg/g at baseline

End point title	Changes in urinary albumin: creatinine ratio (UACR) from baseline to Week 12 for subjects with UACR ≥30 mg/g at baseline

End point description:

Effect of KBP-5074 on UACR by assessing changes in UACR for subjects with UACR ≥30 mg/g at baseline, was evaluated.
The UACR Population was defined as all randomised subjects, after removal of subjects from site 508, who received at least 1 dose of randomised study drug, had a baseline UACR measurement, had UACR ≥30 mg/g at baseline, and had at least 1 post-dose UACR measurement.

End point type	Secondary

End point timeframe:

From baseline to Week 12

End point values	KBP-5074	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	204	203		
Units: mg/g (milligram/gram)				
median (full range (min-max))	-80.43 (-2848.0 to 1091.3)	-12.65 (-3261.0 to 4467.8)		

Statistical analyses

Statistical analysis title	Statistical comparison of KBP-5074 v/s placebo

Statistical analysis description:

Ratio of LS estimate of geometric mean ratio (GMR) of KBP-5074 QD to Placebo QD

Comparison groups	KBP-5074 v Placebo
Number of subjects included in analysis	407
Analysis specification	Pre-specified
Analysis type	other[6]
P-value	= 0.331
Method	ANCOVA
Parameter estimate	Ratio
Point estimate	0.91
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.76
upper limit	1.09

Notes:

[6] - Adjusted GMRs were estimated using an ANCOVA model with change in log-transformed UACR from baseline to Week 12 as the outcome variable.

Secondary: Percentage changes in UACR from baseline to Week 12 and Week 24 for subjects with UACR ≥30 mg/g at baseline

End point title	Percentage changes in UACR from baseline to Week 12 and Week 24 for subjects with UACR ≥30 mg/g at baseline

End point description:

Effect of KBP-5074 on UACR by assessing percentage changes in UACR for subjects with UACR ≥30 mg/g at baseline, was evaluated.

The UACR Population was defined as all randomised subjects, after removal of subjects from site 508, who received at least 1 dose of randomised study drug, had a baseline UACR measurement, had UACR ≥30 mg/g at baseline, and had at least 1 post-dose UACR measurement.
Subjects in Placebo QD group were switched to KBP-5074 QD after Week 24.

Here, 'number of subjects analyzed' specifies all subjects evaluated for this endpoint and 'number analyzed in each row (n)' signifies subjects with available data that were analyzed at specific timepoint.

End point type	Secondary

End point timeframe:

From baseline to Week 12 and Week 24

End point values	KBP-5074	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	208	213		
Units: Percentage				
median (full range (min-max))				
Week 12 (n = 204; 203)	-22.43 (-98.0 to 342.7)	-9.10 (-99.6 to 3094.4)		
Week 24 (n = 185; 194)	-34.37 (-98.3 to 407.8)	-12.50 (-99.5 to 2865.0)		

Statistical analyses

No statistical analyses for this end point

Secondary: Changes in UACR from baseline to Week 12, Week 24, and Week 48 in subjects with macroalbuminuria

End point title	Changes in UACR from baseline to Week 12, Week 24, and Week 48 in subjects with macroalbuminuria

End point description:

Effect of KBP-5074 on UACR by assessing changes in UACR for subjects with macroalbuminuria (defined as UACR ≥300 mg/g) at baseline, was evaluated.

The UACR Population was defined as all randomised subjects, after removal of subjects from site 508, who received at least 1 dose of randomised study drug, had a baseline UACR measurement, had UACR ≥30 mg/g at baseline, and had at least 1 post-dose UACR measurement.

Here, 'number of subjects analyzed' specifies all subjects evaluated for this endpoint and 'number analyzed in each row (n)' signifies subjects with available data that were analyzed at specific timepoint.

End point type	Secondary

End point timeframe:

From baseline to Week 12, Week 24, and Week 48

End point values	KBP-5074	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	131	122		
Units: mg/g				
median (full range (min-max))				
Week 12 (n = 129; 115)	-252.62 (-2848.0 to 1091.3)	-104.83 (-3261.0 to 4467.8)		
Week 24 (n = 117; 110)	-350.58 (-4503.7 to 1860.8)	-70.30 (-3256.2 to 4716.8)		
Week 48 (n = 53; 53)	-285.12 (-2599.1 to 838.5)	-317.71 (-3567.1 to 4518.3)		

Statistical analyses

Statistical analysis title	Statistical comparison at Week 12

Statistical analysis description:

Ratio of LS estimate of GMR of KBP-5074 QD to Placebo QD
The number of subjects in this analysis were 244.

Comparison groups	Placebo v KBP-5074
Number of subjects included in analysis	253
Analysis specification	Pre-specified
Analysis type	other[7]
P-value	= 0.794
Method	Mixed models analysis
Parameter estimate	Ratio
Point estimate	0.97
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.75
upper limit	1.24

Notes:

[7] - Estimated using a mixed-effect repeated model with change in log of UACR from baseline to Week 12 as the outcome variable. The model used an Unstructured covariance matrix.

Statistical analysis title	Statistical comparison at Week 24

Statistical analysis description:

Ratio of LS estimate of GMR of KBP-5074 QD to Placebo QD
The number of subjects in this analysis were 227.

Comparison groups	KBP-5074 v Placebo

Number of subjects included in analysis	253
Analysis specification	Pre-specified
Analysis type	other[8]
P-value	= 0.004
Method	Mixed models analysis
Parameter estimate	Ratio
Point estimate	0.7
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.55
upper limit	0.89

Notes:

[8] - Estimated using a mixed-effect repeated model with change in log of UACR from baseline to Week 24 as the outcome variable. The model used an Unstructured covariance matrix.

Statistical analysis title	Statistical comparison at Week 48

Statistical analysis description:

Ratio of LS estimate of GMR of KBP-5074 QD to Placebo QD
The number of subjects in this analysis were 106.

Comparison groups	KBP-5074 v Placebo
Number of subjects included in analysis	253
Analysis specification	Pre-specified
Analysis type	other[9]
P-value	= 0.147
Method	Mixed models analysis
Parameter estimate	Ratio
Point estimate	0.7
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.43
upper limit	1.14

Notes:

[9] - Estimated using a mixed-effect repeated model with change in log of UACR from baseline to Week 48 as the outcome variable. The model used an Unstructured covariance matrix.

Secondary: Percentage changes in UACR from baseline to Week 12, Week 24, and Week 48 in subjects with macroalbuminuria

End point title	Percentage changes in UACR from baseline to Week 12, Week 24, and Week 48 in subjects with macroalbuminuria

End point description:

Effect of KBP-5074 on UACR by assessing percentage changes in UACR for subjects with macroalbuminuria (defined as UACR ≥300 mg/g) at baseline, was evaluated.

The UACR Population was defined as all randomised subjects, after removal of subjects from site 508, who received at least 1 dose of randomised study drug, had a baseline UACR measurement, had UACR ≥30 mg/g at baseline, and had at least 1 post-dose UACR measurement.

Here, 'number of subjects analyzed' specifies all subjects evaluated for this endpoint and 'number analyzed in each row (n)' signifies subjects with available data that were analyzed at specific timepoint.

End point type	Secondary

End point timeframe:

From baseline to Week 12, Week 24, and Week 48

End point values	KBP-5074	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	131	122		
Units: Percentage				
median (full range (min-max))				
Week 12 (n = 129; 115)	-22.54 (-98.0 to 284.0)	-11.40 (-99.6 to 197.5)		
Week 24 (n = 117; 110)	-38.74 (-98.3 to 144.2)	-12.57 (-99.5 to 386.4)		
Week 48 (n = 53; 53)	-40.20 (-99.5 to 196.4)	-47.43 (-99.5 to 1378.4)		

Statistical analyses

No statistical analyses for this end point

Secondary: Change in seated trough cuff DBP from Week 48 to Week 52

End point title	Change in seated trough cuff DBP from Week 48 to Week 52

End point description:

Effect of KBP-5074 on DBP by assessing change in seated trough cuff DBP, was evaluated.

The Randomised Withdrawal Population was defined as all randomised subjects, after removal of subjects from site 508, who were randomised at the Week 48 Visit into the Randomised Double-Blind Withdrawal Period and had at least 1 SBP measurement after the Week 48 Visit.

Observed data for Dropouts too limited for retrieved dropout-based MI. MI using MAR to be used instead.

End point type	Secondary

End point timeframe:

From Week 48 to Week 52

End point values	KBP-5074 - W	Placebo - W		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	0[10]	0[11]		
Units: mm Hg				
arithmetic mean (standard deviation)	()	()		

Notes:

[10] - Observed data for dropouts was too limited for retrieved dropout-based MI.

[11] - Observed data for dropouts was too limited for retrieved dropout-based MI.

Statistical analyses

No statistical analyses for this end point

Secondary: Change in UACR from Week 48 to Week 52 for subjects with UACR ≥30 mg/g at baseline

End point title	Change in UACR from Week 48 to Week 52 for subjects with UACR ≥30 mg/g at baseline

End point description:

Effect of KBP-5074 on UACR by assessing changes in UACR for subjects with UACR ≥30 mg/g at baseline, was evaluated.

The UACR Population was defined as all randomised subjects, after removal of subjects from site 508, who received at least 1 dose of randomised study drug, had a baseline UACR measurement, had UACR ≥30 mg/g at baseline, and had at least 1 post-dose UACR measurement.
The Randomised Withdrawal Population was defined as all randomised subjects, after removal of subjects from site 508, who were randomised at the Week 48 Visit into the Randomised Double-Blind Withdrawal Period and had at least 1 SBP measurement after the Week 48 Visit.

End point type	Secondary

End point timeframe:

From Week 48 to Week 52

End point values	KBP-5074 - W	Placebo - W		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	69	75		
Units: mg/g				
median (full range (min-max))	-17.31 (-523.8 to 5366.4)	9.38 (-1320.7 to 3905.9)		

Statistical analyses

Statistical analysis title	Statistical comparison of KBP-5074 v/s placebo

Statistical analysis description:

Ratio of LS estimate of GMR of KBP-5074 QD to Placebo QD

Comparison groups	KBP-5074 - W v Placebo - W
Number of subjects included in analysis	144
Analysis specification	Pre-specified
Analysis type	other[12]
P-value	= 0.113
Method	ANCOVA
Parameter estimate	Ratio
Point estimate	0.79
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.59
upper limit	1.06

Notes:

[12] - Estimated using an ANCOVA model with change in log of UACR from Week 48 to Week 52 as the outcome variable.

Secondary: Percentage change in UACR from Week 48 to Week 52 in subjects with UACR ≥30 mg/g at baseline

End point title	Percentage change in UACR from Week 48 to Week 52 in subjects with UACR ≥30 mg/g at baseline

End point description:

Effect of KBP-5074 on UACR by assessing percentage changes in UACR for subjects with UACR ≥30 mg/g at baseline, was evaluated.

The UACR Population was defined as all randomised subjects, after removal of subjects from site 508, who received at least 1 dose of randomised study drug, had a baseline UACR measurement, had UACR ≥30 mg/g at baseline, and had at least 1 post-dose UACR measurement.
The Randomised Withdrawal Population was defined as all randomised subjects, after removal of subjects from site 508, who were randomised at the Week 48 Visit into the Randomised Double-Blind Withdrawal Period and had at least 1 SBP measurement after the Week 48 Visit.

End point type	Secondary

End point timeframe:

From Week 48 to Week 52

End point values	KBP-5074 - W	Placebo - W		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	69	75		
Units: Percentage				
median (full range (min-max))	-15.16 (-76.0 to 132.0)	20.23 (-99.5 to 5133.0)		

Statistical analyses

No statistical analyses for this end point

Secondary: Number of subjects with adverse events (AEs) and serious adverse events (SAEs)

End point title	Number of subjects with adverse events (AEs) and serious adverse events (SAEs)

End point description:

The safety and tolerability of KBP-5074 were evaluated.
Treatment emergent adverse event = TEAE.
Selected TEAEs include Hyperkalemia, Hypertension, Hypotension, and eGFR Decrease.

End point type	Secondary

End point timeframe:

Until end of study (EOS) (Week 56) or Unscheduled visit or end of treatment or early termination (up to 32 months)

End point values	KBP-5074	Placebo	KBP-5074 - OL	Placebo - OL
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	281	273	235	234
Units: Subjects				
Any TEAE	154	154	147	139
Any TEAE Related to Study Drug	40	18	33	27
Any Severe TEAEs	12	16	11	8

Any Severe TEAE Related to Study Drug	2	1	0	0
Any TEAE With Outcome of Death	1	0	1	1
Any Fatal TEAE Related to Study Drug	0	0	0	0
Any Serious TEAE (TESAE)	20	30	11	16
Any Non-serious TEAE	151	151	144	137
Any Serious TEAE Related to Study Drug	0	1	0	0
Any TEAE Leading to Discontinuation of Treatment	12	7	7	9
Any TEAE Leading to Discontinuation of Study	9	8	3	3
Any TEAE Leading to Study Drug Reduced	0	2	0	2
Selected TEAEs	69	43	59	72

End point values	KBP-5074 - W	Placebo - W		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	99	107		
Units: Subjects				
Any TEAE	40	35		
Any TEAE Related to Study Drug	5	7		
Any Severe TEAEs	1	1		
Any Severe TEAE Related to Study Drug	0	0		
Any TEAE With Outcome of Death	0	0		
Any Fatal TEAE Related to Study Drug	0	0		
Any Serious TEAE (TESAE)	4	1		
Any Non-serious TEAE	39	35		
Any Serious TEAE Related to Study Drug	0	0		
Any TEAE Leading to Discontinuation of Treatment	2	1		
Any TEAE Leading to Discontinuation of Study	0	0		
Any TEAE Leading to Study Drug Reduced	1	0		
Selected TEAEs	16	13		

Statistical analyses

No statistical analyses for this end point

Secondary: Changes in seated trough cuff DBP from baseline to Week 24

End point title	Changes in seated trough cuff DBP from baseline to Week 24

End point description:

Effect of KBP-5074 on DBP by assessing change in seated trough cuff DBP, was evaluated.

The ITT Population was defined as all randomised subjects after removal of subjects from site 508.

End point type	Secondary

End point timeframe:

From baseline to Week 24

End point values	KBP-5074	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	242	232		
Units: mm Hg				
arithmetic mean (standard deviation)	-6.3 (± 12.09)	-6.7 (± 12.43)		

Statistical analyses

Statistical analysis title	Statistical comparison of KBP-5074 v/s Placebo
Statistical analysis description:	
Difference (KBP-5074 QD - Placebo QD) between adjusted LS means of change from baseline	
Comparison groups	KBP-5074 v Placebo
Number of subjects included in analysis	474
Analysis specification	Pre-specified
Analysis type	other[13]
P-value	= 0.961
Method	ANCOVA
Parameter estimate	Difference between Adjusted LS Means
Point estimate	0.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	-2.1
upper limit	2.2

Notes:

[13] - Adjusted LS Means were estimated using an ANCOVA model with change in seated trough cuff DBP from baseline to Week 24 as the outcome variable.

Secondary: Changes in seated trough cuff DBP from baseline to Week 48

End point title	Changes in seated trough cuff DBP from baseline to Week 48
End point description:	
Effect of KBP-5074 on DBP by assessing change in seated trough cuff DBP, was evaluated. The ITT Population was defined as all randomised subjects after removal of subjects from site 508.	
End point type	Secondary
End point timeframe:	
From baseline to Week 48	

End point values	KBP-5074 - OL	Placebo - OL		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	140	143		
Units: mm Hg				
arithmetic mean (standard deviation)	-8.1 (± 11.09)	-10.0 (± 12.00)		

Statistical analyses

Statistical analysis title	Statistical comparison of KBP-5074 v/s Placebo

Statistical analysis description:

Difference (KBP-5074 QD -> KBP-5074 QD – Placebo QD -> KBP-5074 QD) between LS Means of change from baseline

Comparison groups	KBP-5074 - OL v Placebo - OL
Number of subjects included in analysis	283
Analysis specification	Pre-specified
Analysis type	other[14]
P-value	= 0.244
Method	Mixed models analysis
Parameter estimate	Difference in LS means
Point estimate	1.4
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1
upper limit	3.8

Notes:

[14] - Estimated using a mixed-effect repeated model with change in seated trough cuff DBP from baseline to Week 48 as the outcome variable. The model used an Unstructured covariance matrix.

Secondary: Changes in UACR from baseline to Week 24 for subjects with UACR ≥30 mg/g at baseline

End point title	Changes in UACR from baseline to Week 24 for subjects with UACR ≥30 mg/g at baseline

End point description:

Effect of KBP-5074 on UACR by assessing changes in UACR for subjects with UACR ≥30 mg/g at baseline, was evaluated.

The UACR Population was defined as all randomised subjects, after removal of subjects from site 508, who received at least 1 dose of randomised study drug, had a baseline UACR measurement, had UACR ≥30 mg/g at baseline, and had at least 1 post-dose UACR measurement.

End point type	Secondary

End point timeframe:

From baseline to Week 24

End point values	KBP-5074	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	185	194		
Units: mg/g				
median (full range (min-max))	-140.90 (-4503.7 to 1860.8)	-11.44 (-3256.2 to 4716.8)		

Statistical analyses

Statistical analysis title	Statistical comparison of KBP-5074 v/s Placebo

Statistical analysis description:

Ratio of Adjusted LS estimate of GMR of KBP-5074 QD to Placebo QD

Comparison groups	KBP-5074 v Placebo
Number of subjects included in analysis	379
Analysis specification	Pre-specified
Analysis type	other[15]
P-value	= 0.028
Method	ANCOVA
Parameter estimate	Ratio
Point estimate	0.77
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.61
upper limit	0.97

Notes:

[15] - Adjusted GMRs are estimated using an ANCOVA model with change in log-transformed UACR from baseline to Week 24 as the outcome variable.

Secondary: Percentage changes in UACR from baseline to Week 12, Week 24, and Week 48 in subjects with microalbuminuria

End point title	Percentage changes in UACR from baseline to Week 12, Week 24, and Week 48 in subjects with microalbuminuria

End point description:

Effect of KBP-5074 on UACR by assessing changes in UACR for subjects with microalbuminuria (defined as UACR ≥30 and <300 mg/g) at baseline, was evaluated.

The UACR Population was defined as all randomised subjects, after removal of subjects from site 508, who received at least 1 dose of randomised study drug, had a baseline UACR measurement, had UACR ≥30 mg/g at baseline, and had at least 1 post-dose UACR measurement.

Here, 'number of subjects analyzed' specifies all subjects evaluated for this endpoint and 'number analyzed in each row (n)' signifies subjects with available data that were analyzed at specific timepoint.

End point type	Secondary

End point timeframe:

From baseline to Week 12, Week 24, and Week 48

End point values	KBP-5074	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	77	91		
Units: Percentage				
median (full range (min-max))				
Week 12 (n = 75; 88)	-22.23 (-91.0 to 342.7)	-6.44 (-89.9 to 3094.4)		
Week 24 (n = 68; 84)	-27.93 (-91.5 to 407.8)	-12.27 (-92.2 to 2865.0)		
Week 48 (n = 40; 47)	-27.39 (-95.1 to 1977.5)	-11.39 (-80.2 to 2976.1)		

Statistical analyses

No statistical analyses for this end point

Secondary: Changes in UACR from baseline to Week 12, Week 24, and Week 48 in subjects with microalbuminuria

End point title	Changes in UACR from baseline to Week 12, Week 24, and Week 48 in subjects with microalbuminuria

End point description:

Effect of KBP-5074 on UACR by assessing changes in UACR for subjects with microalbuminuria (defined as UACR ≥30 and <300 mg/g) at baseline, was evaluated.

The UACR Population was defined as all randomised subjects, after removal of subjects from site 508, who received at least 1 dose of randomised study drug, had a baseline UACR measurement, had UACR ≥30 mg/g at baseline, and had at least 1 post-dose UACR measurement.

Here, 'number of subjects analyzed' specifies all subjects evaluated for this endpoint and 'number analyzed in each row (n)' signifies subjects with available data that were analyzed at specific timepoint.

End point type	Secondary

End point timeframe:

From baseline to Week 12, Week 24, and Week 48

End point values	KBP-5074	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	77	91		
Units: mg/g				
median (full range (min-max))				
Week 12 (n = 75; 88)	-10.98 (-180.4 to 503.5)	-5.46 (-248.8 to 1095.4)		
Week 24 (n = 68; 84)	-16.96 (-208.5 to 516.0)	-7.32 (-214.6 to 1127.2)		
Week 48 (n = 40; 47)	-23.75 (-248.4 to 1715.6)	-7.05 (-231.0 to 1622.1)		

Statistical analyses

Statistical analysis title	Statistical comparison at Week 12

Statistical analysis description:

Ratio of LS estimate of GMR of KBP-5074 QD to Placebo QD
Number of subjects in this analysis were 163.

Comparison groups	KBP-5074 v Placebo
Number of subjects included in analysis	168
Analysis specification	Pre-specified
Analysis type	other[16]
P-value	= 0.167
Method	Mixed models analysis
Parameter estimate	Ratio
Point estimate	0.85
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.67
upper limit	1.07

Notes:

[16] - Estimated using a mixed-effect repeated model with change in log of UACR from baseline to Week 12 as the outcome variable. The model used an Unstructured covariance matrix.

Statistical analysis title	Statistical comparison at Week 24

Statistical analysis description:

Ratio of LS estimate of GMR of KBP-5074 QD to Placebo QD
Number of subjects in this analysis were 152.

Comparison groups	KBP-5074 v Placebo
Number of subjects included in analysis	168
Analysis specification	Pre-specified
Analysis type	other[17]
P-value	= 0.09
Method	Mixed models analysis
Parameter estimate	Ratio
Point estimate	0.79
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.6
upper limit	1.04

Notes:

[17] - Estimated using a mixed-effect repeated model with change in log of UACR from baseline to Week 24 as the outcome variable. The model used an Unstructured covariance matrix.

Statistical analysis title	Statistical comparison at Week 48

Statistical analysis description:

Ratio of LS estimate of GMR of KBP-5074 QD to Placebo QD
Number of subjects in this analysis were 87.

Comparison groups	KBP-5074 v Placebo

Number of subjects included in analysis	168
Analysis specification	Pre-specified
Analysis type	other[18]
P-value	= 0.642
Method	Mixed models analysis
Parameter estimate	Ratio
Point estimate	0.91
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.6
upper limit	1.36

Notes:

[18] - Estimated using a mixed-effect repeated model with change in log of UACR from baseline to Week 48 as the outcome variable. The model used an Unstructured covariance matrix.

Secondary: Change in UACR from Week 48 to Week 52 in subjects with macroalbuminuria

End point title	Change in UACR from Week 48 to Week 52 in subjects with macroalbuminuria

End point description:

Effect of KBP-5074 on UACR by assessing changes in UACR for subjects with macroalbuminuria (defined as UACR ≥300 mg/g) at baseline, was evaluated.

The UACR Population was defined as all randomised subjects, after removal of subjects from site 508, who received at least 1 dose of randomised study drug, had a baseline UACR measurement, had UACR ≥30 mg/g at baseline, and had at least 1 post-dose UACR measurement.
The Randomised Withdrawal Population was defined as all randomised subjects, after removal of subjects from site 508, who were randomised at the Week 48 Visit into the Randomised Double-Blind Withdrawal Period and had at least 1 SBP measurement after the Week 48 Visit.

End point type	Secondary

End point timeframe:

From Week 48 to Week 52

End point values	KBP-5074 - W	Placebo - W		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	37	37		
Units: mg/g				
median (full range (min-max))	-42.15 (-523.8 to 5366.4)	13.66 (-1320.7 to 3905.9)		

Statistical analyses

Statistical analysis title	Statistical comparison of KBP-5074 v/s placebo

Statistical analysis description:

Ratio of LS estimate of GMR of KBP-5074 QD to Placebo QD

Comparison groups	KBP-5074 - W v Placebo - W

Number of subjects included in analysis	74
Analysis specification	Pre-specified
Analysis type	other[19]
P-value	= 0.636
Method	ANCOVA
Parameter estimate	Ratio
Point estimate	0.88
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.51
upper limit	1.51

Notes:

[19] - Estimated using an ANCOVA model with change in log of UACR from Week 48 to Week 52 as the outcome variable.

Secondary: Percentage change in UACR from Week 48 to Week 52 in subjects with macroalbuminuria

End point title	Percentage change in UACR from Week 48 to Week 52 in subjects with macroalbuminuria

End point description:

Effect of KBP-5074 on UACR by assessing changes in UACR for subjects with macroalbuminuria (defined as UACR ≥300 mg/g) at baseline, was evaluated.

The UACR Population was defined as all randomised subjects, after removal of subjects from site 508, who received at least 1 dose of randomised study drug, had a baseline UACR measurement, had UACR ≥30 mg/g at baseline, and had at least 1 post-dose UACR measurement.
The Randomised Withdrawal Population was defined as all randomised subjects, after removal of subjects from site 508, who were randomised at the Week 48 Visit into the Randomised Double-Blind Withdrawal Period and had at least 1 SBP measurement after the Week 48 Visit.

End point type	Secondary

End point timeframe:

From Week 48 to Week 52

End point values	KBP-5074 - W	Placebo - W		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	37	37		
Units: Percentage				
median (full range (min-max))	-11.98 (-76.0 to 109.7)	7.64 (-99.5 to 5133.0)		

Statistical analyses

No statistical analyses for this end point

Secondary: Change in UACR from Week 48 to Week 52 in subjects with microalbuminuria

End point title	Change in UACR from Week 48 to Week 52 in subjects with microalbuminuria

End point description:

Effect of KBP-5074 on UACR by assessing changes in UACR for subjects with microalbuminuria (defined as UACR ≥30 and <300 mg/g) at baseline, was evaluated.

The UACR Population was defined as all randomised subjects, after removal of subjects from site 508, who received at least 1 dose of randomised study drug, had a baseline UACR measurement, had UACR ≥30 mg/g at baseline, and had at least 1 post-dose UACR measurement.
The Randomised Withdrawal Population was defined as all randomised subjects, after removal of subjects from site 508, who were randomised at the Week 48 Visit into the Randomised Double-Blind Withdrawal Period and had at least 1 SBP measurement after the Week 48 Visit.

End point type	Secondary

End point timeframe:

From Week 48 to Week 52

End point values	KBP-5074 - W	Placebo - W		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	32	38		
Units: mg/g				
median (full range (min-max))	-11.76 (-274.8 to 24.2)	9.07 (-561.4 to 1547.4)		

Statistical analyses

Statistical analysis title	Statistical comparison of KBP-5074 v/s placebo

Statistical analysis description:

Ratio of LS estimate of GMR of KBP-5074 QD to Placebo QD

Comparison groups	KBP-5074 - W v Placebo - W
Number of subjects included in analysis	70
Analysis specification	Pre-specified
Analysis type	other[20]
P-value	< 0.001
Method	ANCOVA
Parameter estimate	Ratio
Point estimate	0.68
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.55
upper limit	0.83

Notes:

[20] - Estimated using an ANCOVA model with change in log of UACR from Week 48 to Week 52 as the outcome variable.

Secondary: Percentage change in UACR from Week 48 to Week 52 in subjects with microalbuminuria

End point title	Percentage change in UACR from Week 48 to Week 52 in subjects with microalbuminuria

End point description:

Effect of KBP-5074 on UACR by assessing changes in UACR for subjects with microalbuminuria (defined

as UACR ≥30 and <300 mg/g) at baseline, was evaluated.

The UACR Population was defined as all randomised subjects, after removal of subjects from site 508, who received at least 1 dose of randomised study drug, had a baseline UACR measurement, had UACR ≥30 mg/g at baseline, and had at least 1 post-dose UACR measurement.
The Randomised Withdrawal Population was defined as all randomised subjects, after removal of subjects from site 508, who were randomised at the Week 48 Visit into the Randomised Double-Blind Withdrawal Period and had at least 1 SBP measurement after the Week 48 Visit.

End point type	Secondary
End point timeframe:	
From Week 48 to Week 52	

End point values	KBP-5074 - W	Placebo - W		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	32	38		
Units: Percentage				
median (full range (min-max))	-15.85 (-57.8 to 132.0)	26.84 (-64.2 to 246.0)		

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information	
Timeframe for reporting adverse events:	
Until end of study (EOS) (Week 56) or Unscheduled visit or end of treatment or early termination (up to 32 months)	
Adverse event reporting additional description:	
The Safety Population was defined as all randomised subjects, after removal of subjects from site 508, who received at least 1 dose of randomised study drug.	
Assessment type	Non-systematic

Dictionary used	
Dictionary name	MedDRA
Dictionary version	27.0

Reporting groups	
Reporting group title	KBP-5074
Reporting group description:	
Subjects received 0.25 mg to a maximum dose of 0.5 mg of KBP-5074 QD.	
Reporting group title	Placebo
Reporting group description:	
Subjects received placebo matching to KBP-5074 QD.	
Reporting group title	KBP-5074 - OL
Reporting group description:	
Subjects received 0.25 mg to a maximum dose of 0.5 mg of KBP-5074 QD.	
Reporting group title	Placebo - OL
Reporting group description:	
Subjects received placebo matching to KBP-5074 QD.	
Reporting group title	KBP-5074 - W
Reporting group description:	
Subjects received 0.25 mg to a maximum dose of 0.5 mg of KBP-5074 QD.	
Reporting group title	Placebo - W
Reporting group description:	
Subjects received placebo matching to KBP-5074 QD.	

Serious adverse events	KBP-5074	Placebo	KBP-5074 - OL
Total subjects affected by serious adverse events			
subjects affected / exposed	20 / 281 (7.12%)	30 / 273 (10.99%)	11 / 235 (4.68%)
number of deaths (all causes)	1	0	1
number of deaths resulting from adverse events	1	0	1
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Prostate cancer			
subjects affected / exposed	0 / 281 (0.00%)	1 / 273 (0.37%)	0 / 235 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Malignant melanoma in situ			

subjects affected / exposed	0 / 281 (0.00%)	0 / 273 (0.00%)	0 / 235 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular disorders			
Aortic stenosis			
subjects affected / exposed	1 / 281 (0.36%)	0 / 273 (0.00%)	0 / 235 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Peripheral arterial occlusive disease			
subjects affected / exposed	1 / 281 (0.36%)	0 / 273 (0.00%)	0 / 235 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Peripheral artery thrombosis			
subjects affected / exposed	1 / 281 (0.36%)	0 / 273 (0.00%)	0 / 235 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypotension			
subjects affected / exposed	0 / 281 (0.00%)	1 / 273 (0.37%)	0 / 235 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Aortic dissection			
subjects affected / exposed	0 / 281 (0.00%)	0 / 273 (0.00%)	1 / 235 (0.43%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Shock			
subjects affected / exposed	0 / 281 (0.00%)	0 / 273 (0.00%)	1 / 235 (0.43%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Orthostatic hypotension			
subjects affected / exposed	0 / 281 (0.00%)	0 / 273 (0.00%)	0 / 235 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Venous thrombosis limb			

subjects affected / exposed	0 / 281 (0.00%)	0 / 273 (0.00%)	0 / 235 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Death			
subjects affected / exposed	1 / 281 (0.36%)	0 / 273 (0.00%)	0 / 235 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Immune system disorders			
Drug hypersensitivity			
subjects affected / exposed	1 / 281 (0.36%)	0 / 273 (0.00%)	0 / 235 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Acute respiratory failure			
subjects affected / exposed	2 / 281 (0.71%)	2 / 273 (0.73%)	0 / 235 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Asthma			
subjects affected / exposed	0 / 281 (0.00%)	2 / 273 (0.73%)	0 / 235 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Chronic obstructive pulmonary disease			
subjects affected / exposed	0 / 281 (0.00%)	2 / 273 (0.73%)	0 / 235 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sleep apnoea syndrome			
subjects affected / exposed	0 / 281 (0.00%)	1 / 273 (0.37%)	0 / 235 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Epistaxis			

subjects affected / exposed	0 / 281 (0.00%)	0 / 273 (0.00%)	0 / 235 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lung opacity			
subjects affected / exposed	0 / 281 (0.00%)	0 / 273 (0.00%)	0 / 235 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psychiatric disorders			
Delirium			
subjects affected / exposed	0 / 281 (0.00%)	1 / 273 (0.37%)	0 / 235 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Product issues			
Device loosening			
subjects affected / exposed	1 / 281 (0.36%)	0 / 273 (0.00%)	0 / 235 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Device occlusion			
subjects affected / exposed	0 / 281 (0.00%)	0 / 273 (0.00%)	1 / 235 (0.43%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Investigations			
Electrocardiogram T wave abnormal			
subjects affected / exposed	1 / 281 (0.36%)	0 / 273 (0.00%)	0 / 235 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Glomerular filtration rate decreased			
subjects affected / exposed	0 / 281 (0.00%)	2 / 273 (0.73%)	0 / 235 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ejection fraction decreased			
subjects affected / exposed	0 / 281 (0.00%)	0 / 273 (0.00%)	0 / 235 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Injury, poisoning and procedural complications			
Fall			
subjects affected / exposed	0 / 281 (0.00%)	1 / 273 (0.37%)	0 / 235 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Joint injury			
subjects affected / exposed	0 / 281 (0.00%)	1 / 273 (0.37%)	0 / 235 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Traumatic intracranial haemorrhage			
subjects affected / exposed	0 / 281 (0.00%)	0 / 273 (0.00%)	0 / 235 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Wound dehiscence			
subjects affected / exposed	0 / 281 (0.00%)	0 / 273 (0.00%)	0 / 235 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
Cardiac failure congestive			
subjects affected / exposed	2 / 281 (0.71%)	1 / 273 (0.37%)	1 / 235 (0.43%)
occurrences causally related to treatment / all	0 / 2	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac failure			
subjects affected / exposed	1 / 281 (0.36%)	2 / 273 (0.73%)	1 / 235 (0.43%)
occurrences causally related to treatment / all	0 / 1	0 / 2	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Angina unstable			
subjects affected / exposed	1 / 281 (0.36%)	0 / 273 (0.00%)	0 / 235 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Atrial fibrillation			
subjects affected / exposed	1 / 281 (0.36%)	0 / 273 (0.00%)	0 / 235 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Coronary artery disease			
subjects affected / exposed	1 / 281 (0.36%)	0 / 273 (0.00%)	0 / 235 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bradycardia			
subjects affected / exposed	0 / 281 (0.00%)	1 / 273 (0.37%)	0 / 235 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sinus node dysfunction			
subjects affected / exposed	0 / 281 (0.00%)	1 / 273 (0.37%)	1 / 235 (0.43%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Atrioventricular block			
subjects affected / exposed	0 / 281 (0.00%)	0 / 273 (0.00%)	0 / 235 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac failure acute			
subjects affected / exposed	0 / 281 (0.00%)	0 / 273 (0.00%)	0 / 235 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Mitral valve incompetence			
subjects affected / exposed	0 / 281 (0.00%)	0 / 273 (0.00%)	0 / 235 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nodal rhythm			
subjects affected / exposed	0 / 281 (0.00%)	0 / 273 (0.00%)	0 / 235 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tricuspid valve incompetence			
subjects affected / exposed	0 / 281 (0.00%)	0 / 273 (0.00%)	0 / 235 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			

Ischaemic stroke			
subjects affected / exposed	1 / 281 (0.36%)	0 / 273 (0.00%)	0 / 235 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Loss of consciousness			
subjects affected / exposed	1 / 281 (0.36%)	0 / 273 (0.00%)	0 / 235 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cerebral infarction			
subjects affected / exposed	0 / 281 (0.00%)	3 / 273 (1.10%)	0 / 235 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 3	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cerebrovascular accident			
subjects affected / exposed	0 / 281 (0.00%)	1 / 273 (0.37%)	0 / 235 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolic encephalopathy			
subjects affected / exposed	0 / 281 (0.00%)	1 / 273 (0.37%)	0 / 235 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Transient ischaemic attack			
subjects affected / exposed	0 / 281 (0.00%)	0 / 273 (0.00%)	0 / 235 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	0 / 281 (0.00%)	0 / 273 (0.00%)	0 / 235 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Iron deficiency anaemia			
subjects affected / exposed	0 / 281 (0.00%)	0 / 273 (0.00%)	0 / 235 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Eye disorders			

Cataract			
subjects affected / exposed	0 / 281 (0.00%)	1 / 273 (0.37%)	0 / 235 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diabetic retinopathy			
subjects affected / exposed	0 / 281 (0.00%)	1 / 273 (0.37%)	0 / 235 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vitreous haemorrhage			
subjects affected / exposed	0 / 281 (0.00%)	1 / 273 (0.37%)	0 / 235 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Duodenal ulcer			
subjects affected / exposed	1 / 281 (0.36%)	0 / 273 (0.00%)	1 / 235 (0.43%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal haemorrhage			
subjects affected / exposed	0 / 281 (0.00%)	1 / 273 (0.37%)	0 / 235 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorder			
subjects affected / exposed	0 / 281 (0.00%)	0 / 273 (0.00%)	0 / 235 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary disorders			
Cholecystitis			
subjects affected / exposed	1 / 281 (0.36%)	0 / 273 (0.00%)	0 / 235 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
Chronic kidney disease			

subjects affected / exposed	5 / 281 (1.78%)	4 / 273 (1.47%)	1 / 235 (0.43%)
occurrences causally related to treatment / all	0 / 5	1 / 4	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Acute kidney injury			
subjects affected / exposed	3 / 281 (1.07%)	1 / 273 (0.37%)	1 / 235 (0.43%)
occurrences causally related to treatment / all	0 / 3	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
End stage renal disease			
subjects affected / exposed	0 / 281 (0.00%)	1 / 273 (0.37%)	0 / 235 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Tenosynovitis			
subjects affected / exposed	1 / 281 (0.36%)	0 / 273 (0.00%)	0 / 235 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rhabdomyolysis			
subjects affected / exposed	0 / 281 (0.00%)	1 / 273 (0.37%)	0 / 235 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fistula			
subjects affected / exposed	0 / 281 (0.00%)	0 / 273 (0.00%)	1 / 235 (0.43%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Osteoarthritis			
subjects affected / exposed	0 / 281 (0.00%)	0 / 273 (0.00%)	0 / 235 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Pneumonia			
subjects affected / exposed	3 / 281 (1.07%)	7 / 273 (2.56%)	1 / 235 (0.43%)
occurrences causally related to treatment / all	0 / 3	0 / 7	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Urinary tract infection			
subjects affected / exposed	2 / 281 (0.71%)	2 / 273 (0.73%)	1 / 235 (0.43%)
occurrences causally related to treatment / all	0 / 3	0 / 3	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
COVID-19			
subjects affected / exposed	0 / 281 (0.00%)	4 / 273 (1.47%)	0 / 235 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 4	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sepsis			
subjects affected / exposed	0 / 281 (0.00%)	0 / 273 (0.00%)	2 / 235 (0.85%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Carbuncle			
subjects affected / exposed	0 / 281 (0.00%)	0 / 273 (0.00%)	1 / 235 (0.43%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infected skin ulcer			
subjects affected / exposed	0 / 281 (0.00%)	0 / 273 (0.00%)	1 / 235 (0.43%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bronchitis			
subjects affected / exposed	0 / 281 (0.00%)	0 / 273 (0.00%)	0 / 235 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
Hyperkalaemia			
subjects affected / exposed	3 / 281 (1.07%)	1 / 273 (0.37%)	0 / 235 (0.00%)
occurrences causally related to treatment / all	0 / 3	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dehydration			
subjects affected / exposed	1 / 281 (0.36%)	0 / 273 (0.00%)	0 / 235 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diabetic ketoacidosis			

subjects affected / exposed	0 / 281 (0.00%)	1 / 273 (0.37%)	0 / 235 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypoglycaemia			
subjects affected / exposed	0 / 281 (0.00%)	1 / 273 (0.37%)	0 / 235 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyponatraemia			
subjects affected / exposed	0 / 281 (0.00%)	0 / 273 (0.00%)	1 / 235 (0.43%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	Placebo - OL	KBP-5074 - W	Placebo - W
Total subjects affected by serious adverse events			
subjects affected / exposed	16 / 234 (6.84%)	4 / 99 (4.04%)	1 / 107 (0.93%)
number of deaths (all causes)	1	0	0
number of deaths resulting from adverse events	1	0	0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Prostate cancer			
subjects affected / exposed	0 / 234 (0.00%)	1 / 99 (1.01%)	0 / 107 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Malignant melanoma in situ			
subjects affected / exposed	0 / 234 (0.00%)	1 / 99 (1.01%)	0 / 107 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular disorders			
Aortic stenosis			
subjects affected / exposed	1 / 234 (0.43%)	0 / 99 (0.00%)	0 / 107 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Peripheral arterial occlusive disease			

subjects affected / exposed	0 / 234 (0.00%)	0 / 99 (0.00%)	0 / 107 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Peripheral artery thrombosis			
subjects affected / exposed	0 / 234 (0.00%)	0 / 99 (0.00%)	0 / 107 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypotension			
subjects affected / exposed	0 / 234 (0.00%)	0 / 99 (0.00%)	0 / 107 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Aortic dissection			
subjects affected / exposed	0 / 234 (0.00%)	0 / 99 (0.00%)	0 / 107 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Shock			
subjects affected / exposed	0 / 234 (0.00%)	0 / 99 (0.00%)	0 / 107 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Orthostatic hypotension			
subjects affected / exposed	1 / 234 (0.43%)	0 / 99 (0.00%)	0 / 107 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Venous thrombosis limb			
subjects affected / exposed	1 / 234 (0.43%)	0 / 99 (0.00%)	0 / 107 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Death			
subjects affected / exposed	0 / 234 (0.00%)	0 / 99 (0.00%)	0 / 107 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Immune system disorders			

Drug hypersensitivity			
subjects affected / exposed	0 / 234 (0.00%)	0 / 99 (0.00%)	0 / 107 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Acute respiratory failure			
subjects affected / exposed	1 / 234 (0.43%)	0 / 99 (0.00%)	0 / 107 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Asthma			
subjects affected / exposed	0 / 234 (0.00%)	0 / 99 (0.00%)	0 / 107 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Chronic obstructive pulmonary disease			
subjects affected / exposed	0 / 234 (0.00%)	0 / 99 (0.00%)	0 / 107 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sleep apnoea syndrome			
subjects affected / exposed	1 / 234 (0.43%)	0 / 99 (0.00%)	0 / 107 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Epistaxis			
subjects affected / exposed	1 / 234 (0.43%)	0 / 99 (0.00%)	0 / 107 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Lung opacity			
subjects affected / exposed	1 / 234 (0.43%)	0 / 99 (0.00%)	0 / 107 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psychiatric disorders			
Delirium			

subjects affected / exposed	0 / 234 (0.00%)	0 / 99 (0.00%)	0 / 107 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Product issues			
Device loosening			
subjects affected / exposed	0 / 234 (0.00%)	0 / 99 (0.00%)	0 / 107 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Device occlusion			
subjects affected / exposed	0 / 234 (0.00%)	0 / 99 (0.00%)	0 / 107 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Investigations			
Electrocardiogram T wave abnormal			
subjects affected / exposed	0 / 234 (0.00%)	0 / 99 (0.00%)	0 / 107 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Glomerular filtration rate decreased			
subjects affected / exposed	1 / 234 (0.43%)	0 / 99 (0.00%)	0 / 107 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ejection fraction decreased			
subjects affected / exposed	1 / 234 (0.43%)	0 / 99 (0.00%)	1 / 107 (0.93%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
Fall			
subjects affected / exposed	0 / 234 (0.00%)	0 / 99 (0.00%)	0 / 107 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Joint injury			
subjects affected / exposed	0 / 234 (0.00%)	0 / 99 (0.00%)	0 / 107 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Traumatic intracranial haemorrhage			
subjects affected / exposed	1 / 234 (0.43%)	0 / 99 (0.00%)	0 / 107 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Wound dehiscence			
subjects affected / exposed	1 / 234 (0.43%)	0 / 99 (0.00%)	0 / 107 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
Cardiac failure congestive			
subjects affected / exposed	3 / 234 (1.28%)	0 / 99 (0.00%)	0 / 107 (0.00%)
occurrences causally related to treatment / all	0 / 3	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac failure			
subjects affected / exposed	2 / 234 (0.85%)	0 / 99 (0.00%)	0 / 107 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Angina unstable			
subjects affected / exposed	0 / 234 (0.00%)	0 / 99 (0.00%)	0 / 107 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Atrial fibrillation			
subjects affected / exposed	2 / 234 (0.85%)	0 / 99 (0.00%)	0 / 107 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Coronary artery disease			
subjects affected / exposed	0 / 234 (0.00%)	0 / 99 (0.00%)	0 / 107 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bradycardia			
subjects affected / exposed	0 / 234 (0.00%)	0 / 99 (0.00%)	0 / 107 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sinus node dysfunction			

subjects affected / exposed	1 / 234 (0.43%)	0 / 99 (0.00%)	0 / 107 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Atrioventricular block			
subjects affected / exposed	1 / 234 (0.43%)	0 / 99 (0.00%)	0 / 107 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac failure acute			
subjects affected / exposed	1 / 234 (0.43%)	1 / 99 (1.01%)	0 / 107 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Mitral valve incompetence			
subjects affected / exposed	1 / 234 (0.43%)	0 / 99 (0.00%)	0 / 107 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nodal rhythm			
subjects affected / exposed	1 / 234 (0.43%)	0 / 99 (0.00%)	0 / 107 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tricuspid valve incompetence			
subjects affected / exposed	1 / 234 (0.43%)	0 / 99 (0.00%)	0 / 107 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Ischaemic stroke			
subjects affected / exposed	0 / 234 (0.00%)	0 / 99 (0.00%)	0 / 107 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Loss of consciousness			
subjects affected / exposed	0 / 234 (0.00%)	0 / 99 (0.00%)	0 / 107 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cerebral infarction			

subjects affected / exposed	0 / 234 (0.00%)	0 / 99 (0.00%)	0 / 107 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cerebrovascular accident			
subjects affected / exposed	0 / 234 (0.00%)	0 / 99 (0.00%)	0 / 107 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolic encephalopathy			
subjects affected / exposed	0 / 234 (0.00%)	0 / 99 (0.00%)	0 / 107 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Transient ischaemic attack			
subjects affected / exposed	1 / 234 (0.43%)	0 / 99 (0.00%)	0 / 107 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	1 / 234 (0.43%)	0 / 99 (0.00%)	0 / 107 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Iron deficiency anaemia			
subjects affected / exposed	0 / 234 (0.00%)	1 / 99 (1.01%)	0 / 107 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Eye disorders			
Cataract			
subjects affected / exposed	0 / 234 (0.00%)	0 / 99 (0.00%)	0 / 107 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diabetic retinopathy			
subjects affected / exposed	0 / 234 (0.00%)	0 / 99 (0.00%)	0 / 107 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vitreous haemorrhage			

subjects affected / exposed	0 / 234 (0.00%)	0 / 99 (0.00%)	0 / 107 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Duodenal ulcer			
subjects affected / exposed	0 / 234 (0.00%)	0 / 99 (0.00%)	0 / 107 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal haemorrhage			
subjects affected / exposed	0 / 234 (0.00%)	0 / 99 (0.00%)	0 / 107 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorder			
subjects affected / exposed	1 / 234 (0.43%)	0 / 99 (0.00%)	0 / 107 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary disorders			
Cholecystitis			
subjects affected / exposed	0 / 234 (0.00%)	0 / 99 (0.00%)	0 / 107 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
Chronic kidney disease			
subjects affected / exposed	0 / 234 (0.00%)	0 / 99 (0.00%)	0 / 107 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Acute kidney injury			
subjects affected / exposed	1 / 234 (0.43%)	0 / 99 (0.00%)	0 / 107 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
End stage renal disease			
subjects affected / exposed	0 / 234 (0.00%)	0 / 99 (0.00%)	0 / 107 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Musculoskeletal and connective tissue disorders			
Tenosynovitis			
subjects affected / exposed	0 / 234 (0.00%)	0 / 99 (0.00%)	0 / 107 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rhabdomyolysis			
subjects affected / exposed	0 / 234 (0.00%)	0 / 99 (0.00%)	0 / 107 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fistula			
subjects affected / exposed	0 / 234 (0.00%)	0 / 99 (0.00%)	0 / 107 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Osteoarthritis			
subjects affected / exposed	0 / 234 (0.00%)	1 / 99 (1.01%)	0 / 107 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Pneumonia			
subjects affected / exposed	3 / 234 (1.28%)	0 / 99 (0.00%)	0 / 107 (0.00%)
occurrences causally related to treatment / all	0 / 3	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary tract infection			
subjects affected / exposed	0 / 234 (0.00%)	0 / 99 (0.00%)	0 / 107 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
COVID-19			
subjects affected / exposed	0 / 234 (0.00%)	0 / 99 (0.00%)	0 / 107 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sepsis			
subjects affected / exposed	0 / 234 (0.00%)	0 / 99 (0.00%)	0 / 107 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Carbuncle			
subjects affected / exposed	0 / 234 (0.00%)	0 / 99 (0.00%)	0 / 107 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infected skin ulcer			
subjects affected / exposed	0 / 234 (0.00%)	0 / 99 (0.00%)	0 / 107 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bronchitis			
subjects affected / exposed	1 / 234 (0.43%)	0 / 99 (0.00%)	0 / 107 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
Hyperkalaemia			
subjects affected / exposed	0 / 234 (0.00%)	0 / 99 (0.00%)	0 / 107 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dehydration			
subjects affected / exposed	0 / 234 (0.00%)	0 / 99 (0.00%)	0 / 107 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diabetic ketoacidosis			
subjects affected / exposed	0 / 234 (0.00%)	0 / 99 (0.00%)	0 / 107 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypoglycaemia			
subjects affected / exposed	0 / 234 (0.00%)	0 / 99 (0.00%)	0 / 107 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyponatraemia			
subjects affected / exposed	0 / 234 (0.00%)	0 / 99 (0.00%)	0 / 107 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	KBP-5074	Placebo	KBP-5074 - OL
Total subjects affected by non-serious adverse events			
subjects affected / exposed	39 / 281 (13.88%)	16 / 273 (5.86%)	40 / 235 (17.02%)
Investigations			
Glomerular filtration rate decreased			
subjects affected / exposed	16 / 281 (5.69%)	9 / 273 (3.30%)	17 / 235 (7.23%)
occurrences (all)	19	9	26
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	0 / 281 (0.00%)	0 / 273 (0.00%)	0 / 235 (0.00%)
occurrences (all)	0	0	0
Metabolism and nutrition disorders			
Hyperkalaemia			
subjects affected / exposed	25 / 281 (8.90%)	9 / 273 (3.30%)	28 / 235 (11.91%)
occurrences (all)	30	14	34

Non-serious adverse events	Placebo - OL	KBP-5074 - W	Placebo - W
Total subjects affected by non-serious adverse events			
subjects affected / exposed	43 / 234 (18.38%)	13 / 99 (13.13%)	6 / 107 (5.61%)
Investigations			
Glomerular filtration rate decreased			
subjects affected / exposed	15 / 234 (6.41%)	7 / 99 (7.07%)	6 / 107 (5.61%)
occurrences (all)	21	10	8
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	0 / 234 (0.00%)	6 / 99 (6.06%)	0 / 107 (0.00%)
occurrences (all)	0	6	0
Metabolism and nutrition disorders			
Hyperkalaemia			
subjects affected / exposed	31 / 234 (13.25%)	0 / 99 (0.00%)	0 / 107 (0.00%)
occurrences (all)	47	0	0

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
30 March 2022	Amendment 1 The purpose of this amendment was to update the inclusion and exclusion criteria and add a risk assessment for the Coronavirus Disease Pandemic.
22 December 2023	Amendment 2 The main purpose of this protocol amendment was to provide statistical analysis plan alignment, clarifications including biomarker analysis to include urine sampling, treatment emergent adverse events, disclosure and publication policy, concomitant medication with emergency use medicines, and administrative change to update company address. Other minor edits were made throughout the protocol amendment for minor clarification and to correct grammatical errors, inconsistencies, and formatting. The Schedule of Study Procedures and clinical laboratory analytes were updated to reflect changes.

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? Yes

Date	Interruption	Restart date
24 April 2024	Based on a pre-planned interim analysis of this study, an Independent Data Monitoring Committee (IDMC) concluded on 24 Apr 2024 that the study met the prespecified futility criteria – meaning that the study did not meet its primary endpoint of change in SBP from baseline to Week 12. Based on the IDMC futility determination, it was decided to early terminate the study. Additionally, data from one study site (site 508) were excluded due to data reliability and integrity concerns related to that site.	-

Notes:

Limitations and caveats

Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.

The study was terminated early due to futility of efficacy. All data were analyzed and reported except site 508 due to data reliability and integrity concerns. Sponsorship was transferred from KBP Biosciences to Novo Nordisk after termination.

Notes: